Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease
- 23 June 2025
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (1) , 176-184
Abstract
Objectives: Our previous study revealed a correlation between fecal leukocyte esterase and fecal calprotectin levels. This study assessed the predictive value of fecal leukocyte esterase compared with fecal calprotectin and C-reactive protein of inflammatory bowel disease. Methods: Patients with inflammatory bowel disease who underwent ileocolonoscopy at National Taiwan University Hospital from March 2022 to March 2024 were included. Fecal leukocyte esterase and fecal calprotectin levels from stool samples collected within one month of endoscopy were analyzed. Active ulcerative colitis and Crohn’s disease were defined as Mayo endoscopic score ≥2 or simple endoscopic score for Crohn’s disease ≥7, respectively. Sensitivity, specificity, predictive values, and areas under the receiver operating characteristic curve were calculated using IBM SPSS Statistics 29. Results: Of the 203 patients (100 with ulcerative colitis and 103 with Crohn’s disease), fecal leukocyte esterase levels were significantly correlated with fecal calprotectin levels (r=0.425, p<0.001) and endoscopic severity in ulcerative colitis (r=0.432, p<0.001) and Crohn’s disease (r=0.311, p=0.001). For predicting Mayo endoscopic scores ≥2 in ulcerative colitis using fecal leukocyte esterase, fecal calprotectin, and C-reactive protein, areas under the curve were 0.731, 0.785, and 0.558, respectively. For predicting simple endoscopic scores for Crohn’s disease ≥7, areas under the curve were 0.706, 0.800, and 0.770, respectively. No significant difference was observed between fecal leukocyte esterase and fecal calprotectin. Conclusions: Fecal leukocyte esterase correlates with fecal calprotectin and predicts endoscopic severity in inflammatory bowel disease.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (111-2314-B-002-188-MY3)
- The Liver Disease Prevention and Treatment Research Foundation, Taiwan
- National Taiwan University Hospital (NTUH MS-507)
This publication has 30 references indexed in Scilit:
- A simplified fecal leukocyte esterase strip test results as a low cost, widely available, alternative bowel inflammation biomarkerJournal of the Formosan Medical Association, 2024
- Fecal Leukocyte Esterase, an Alternative Biomarker to Fecal Calprotectin in Inflammatory Bowel Disease: A Pilot SeriesGastro Hep Advances, 2022
- Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2021
- High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination ScoreDigestive Diseases and Sciences, 2016
- Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2016
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2015
- Exam 1: Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After SurgeryGastroenterology, 2015
- Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one yearDigestive and Liver Disease, 2014
- The Abnormal UrinalysisPediatric Clinics of North America, 2006
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004